![Zoetis Inc. Website](https://cdn.finchat.io/215548781.png)
Zoetis Inc.
NYSE-ZTS
Company Overview
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
Name
Zoetis Inc.
CEO
Ms. Kristin C. Peck
Website
www.zoetis.com
Sector
Pharmaceuticals
Year Founded
1952
Profile
Market Cap
$85.73B
EV
$90.92B
Shares Out
453.05M
Revenue
$8,915M
Employees
14,100
Margins
Gross
70.01%
EBITDA
40.89%
Operating
36.09%
Pre-Tax
32.46%
Net
26.29%
FCF
23.59%
Returns (5Yr Avg)
ROA
14.78%
ROTA
122.05%
ROE
51.23%
ROCE
23.85%
ROIC
23.27%
Valuation (TTM)
P/E
—
P/B
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
EV/Gross Profit
—
Valuation (NTM)
Price Target
$216.32
P/E
—
PEG
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
Financial Health
Cash
$1,574M
Net Debt
$5,200M
Debt/Equity
1.37
EBIT/Interest
13.69
Growth (CAGR)
Rev 3Yr
6.35%
Rev 5Yr
8.08%
Rev 10Yr
6.81%
Dil EPS 3Yr
8.52%
Dil EPS 5Yr
12.5%
Dil EPS 10Yr
17.12%
Rev Fwd 2Yr
7.13%
EBITDA Fwd 2Yr
8.42%
EPS Fwd 2Yr
10.06%
EPS LT Growth Est
8.96%
Dividends
Yield
—
Payout
31.55%
DPS
$1.61
DPS Growth 3Yr
21.49%
DPS Growth 5Yr
22.71%
DPS Growth 10Yr
19.4%
DPS Growth Fwd 2Yr
10.74%